Indeed, the INVEST trial found that among patients using ACE inhibitors in combination with CCBs with a history of coronary heart disease and class I obesity had a 48% lower risk of CV-related mortality, compared to normal weight patients [12]. The gene discussed is ACE; the disease is obesity due to melanocortin 4 receptor deficiency.